BioCentury | Mar 25, 2019
Emerging Company Profile

China Oncology Focus: funding combinations

...III testing for hepatocellular carcinoma. Lee’s gained exclusive China rights to it in 2009 from Jennerex...
BioCentury | Nov 23, 2015
Company News

Jennerex Biotherapeutics, Transgene deal

...South Korea), which acquired Jennerex in 2014, and Transgene amended a 2010 deal in which Jennerex...
...are expected to begin next year (see BioCentury, Sept. 13, 2010 & March 24, 2014). Jennerex Biotherapeutics Inc....
BioCentury | Jul 27, 2015
Clinical News

Pexastimogene devacirepvec: Additional Phase Ib data

...gained Pexa-Vec through its 2014 acquisition of Jennerex Biotherapeutics Inc. (see BioCentury, March 24, 2014). In 2012, Jennerex...
BioCentury | Mar 31, 2014
Company News

Tobira management update

...Francisco, Calif. Business: Infectious Hired: Chairman Laurent Fischer as CEO, formerly chairman and CEO of Jennerex Biotherapeutics Inc....
...who resigned; and Christopher Peetz as CFO, formerly VP of finance and corporate development at Jennerex...
BioCentury | Mar 24, 2014
Company News

Jennerex Biotherapeutics, SillaJen deal

...CRO SillaJen completed its acquisition of cancer company Jennerex for up to $150 million in cash...
...By the end of 1Q15, SillaJen plans to begin a Phase III trial to evaluate Jennerex's...
...thymidine kinase - as front-line treatment for advanced liver cancer (see BioCentury, Dec. 9, 2013). Jennerex Biotherapeutics Inc....
BioCentury | Dec 9, 2013
Company News

Jennerex Biotherapeutics, SillaJen deal

...CRO SillaJen is acquiring cancer company Jennerex for up to $150 million in cash in an...
...2007 and owns about 25% of Jennerex, which will become a subsidiary of the CRO. Jennerex...
...& Hachigian is legal advisor to Jennerex. The deal is expected to close next quarter. Jennerex Biotherapeutics Inc....
BioCentury | Nov 27, 2013
Company News

SillaJen acquiring cancer company Jennerex

...CRO SillaJen Inc. (Busan, South Korea) is acquiring cancer company Jennerex Biotherapeutics Inc. (San Francisco, Calif.) for up...
...and already owns about 25% of Jennerex, which will become a subsidiary of the CRO. Jennerex...
...Phase III trial of the product for first-line treatment of hepatocellular carcinoma (HCC). In September, Jennerex's...
BioCentury | Oct 7, 2013
Finance

3Q Stock Wrap-Up: Make it a double

...Discontinues development of ISIS-CRPRx for RA after the antisense inhibitor fails a Phase II trial Jennerex Biotherapeutics Inc./Transgene...
BioCentury | Sep 9, 2013
Clinical News

Pexa-Vec pexastimogene devacirepvec: Phase IIb discontinued

...Orphan Drug designation in the U.S. and Europe for HCC. Transgene has exclusive rights from Jennerex...
...Xetra:BAYN, Leverkusen, Germany) and Onyx Pharmaceuticals Inc. (NASDAQ:ONXX, South San Francisco, Calif.) market Nexavar sorafenib. Jennerex Biotherapeutics Inc....
BioCentury | Sep 5, 2013
Clinical News

Transgene falls on Pexa-Vec miss in second-line HCC

...treatment-refractory colorectal cancer and an exploratory trial for ovarian cancer. Transgene has exclusive rights from Jennerex Biotherapeutics Inc....
Items per page:
1 - 10 of 63
BioCentury | Mar 25, 2019
Emerging Company Profile

China Oncology Focus: funding combinations

...III testing for hepatocellular carcinoma. Lee’s gained exclusive China rights to it in 2009 from Jennerex...
BioCentury | Nov 23, 2015
Company News

Jennerex Biotherapeutics, Transgene deal

...South Korea), which acquired Jennerex in 2014, and Transgene amended a 2010 deal in which Jennerex...
...are expected to begin next year (see BioCentury, Sept. 13, 2010 & March 24, 2014). Jennerex Biotherapeutics Inc....
BioCentury | Jul 27, 2015
Clinical News

Pexastimogene devacirepvec: Additional Phase Ib data

...gained Pexa-Vec through its 2014 acquisition of Jennerex Biotherapeutics Inc. (see BioCentury, March 24, 2014). In 2012, Jennerex...
BioCentury | Mar 31, 2014
Company News

Tobira management update

...Francisco, Calif. Business: Infectious Hired: Chairman Laurent Fischer as CEO, formerly chairman and CEO of Jennerex Biotherapeutics Inc....
...who resigned; and Christopher Peetz as CFO, formerly VP of finance and corporate development at Jennerex...
BioCentury | Mar 24, 2014
Company News

Jennerex Biotherapeutics, SillaJen deal

...CRO SillaJen completed its acquisition of cancer company Jennerex for up to $150 million in cash...
...By the end of 1Q15, SillaJen plans to begin a Phase III trial to evaluate Jennerex's...
...thymidine kinase - as front-line treatment for advanced liver cancer (see BioCentury, Dec. 9, 2013). Jennerex Biotherapeutics Inc....
BioCentury | Dec 9, 2013
Company News

Jennerex Biotherapeutics, SillaJen deal

...CRO SillaJen is acquiring cancer company Jennerex for up to $150 million in cash in an...
...2007 and owns about 25% of Jennerex, which will become a subsidiary of the CRO. Jennerex...
...& Hachigian is legal advisor to Jennerex. The deal is expected to close next quarter. Jennerex Biotherapeutics Inc....
BioCentury | Nov 27, 2013
Company News

SillaJen acquiring cancer company Jennerex

...CRO SillaJen Inc. (Busan, South Korea) is acquiring cancer company Jennerex Biotherapeutics Inc. (San Francisco, Calif.) for up...
...and already owns about 25% of Jennerex, which will become a subsidiary of the CRO. Jennerex...
...Phase III trial of the product for first-line treatment of hepatocellular carcinoma (HCC). In September, Jennerex's...
BioCentury | Oct 7, 2013
Finance

3Q Stock Wrap-Up: Make it a double

...Discontinues development of ISIS-CRPRx for RA after the antisense inhibitor fails a Phase II trial Jennerex Biotherapeutics Inc./Transgene...
BioCentury | Sep 9, 2013
Clinical News

Pexa-Vec pexastimogene devacirepvec: Phase IIb discontinued

...Orphan Drug designation in the U.S. and Europe for HCC. Transgene has exclusive rights from Jennerex...
...Xetra:BAYN, Leverkusen, Germany) and Onyx Pharmaceuticals Inc. (NASDAQ:ONXX, South San Francisco, Calif.) market Nexavar sorafenib. Jennerex Biotherapeutics Inc....
BioCentury | Sep 5, 2013
Clinical News

Transgene falls on Pexa-Vec miss in second-line HCC

...treatment-refractory colorectal cancer and an exploratory trial for ovarian cancer. Transgene has exclusive rights from Jennerex Biotherapeutics Inc....
Items per page:
1 - 10 of 63